Taqman Ehrlichia Canis Test PCR Canine Dog Test Kit Nucleic Acid Amplification

Ehrlichia Canis ( E.C ) Nucleic Acid amplification PCR testing Fluorescent taqman Probe kit

Intended use:

This kit is suitable for the specific detection of Ehrlichia canis (E.C) in Canine EDTA whole blood samples.

Principle:

This kit use Ehrlichia canis conservative design specific gene probe, the probe can with primer amplification area in the middle of a specific binding DNA template, in the process of PCR extension, the circumscribed Taq polymerase enzymes from the 5 'end of fluorescent groups on the probe will be cut down, make it free in the reaction system, thereby quenching groups out of the 3' end, glow, Fluorescence PCR was used to detect Ehrlichia canis nucleic acid in a completely closed reaction system.

Main components:

Sample requirements:

1. Sample type
Canine EDTA whole blood etc.
2. Sample collection and transportation
Sample collection and transportation shall be carried out in accordance with NY/T 541. Samples shall be transported to the laboratory as soon as possible under refrigerated conditions to avoid repeated freeze-thaw.
3. Sample preservation
It can be stored for 24 hours at 2℃~8℃, and can be stored for a long time at -70℃.

Method calibration:

PCR amplification and fluorescence Detection (PCR detection area)
Put each reaction tube into the PCR instrument and perform PCR amplification according to the following procedures:

FAM is selected for detection channels.

Positive judgment value or reference interval

Note: The result is judged to be grey area, which needs to be rechecked. If the recheck result is Ct value < 45 is considered as positive, and no Ct value or Ct value ≥45 is considered as negative.

Operation details please check from IFU!

Bio key Health is a high-tech enterprise with integrating R&D, production and sales&marketing in Guangzhou. Since 2003. Bio Key was founded by the "Thousand Talents Program" entrepreneurial team and the overseas senior automation equipment development engineer team.

The company's core team has been in the field of IVD research and entrepreneurship for more than 10 years, and has mastered a wealth of molecular diagnostic POCT industrial application technology, SmartTRF immune detection technology, RT qPCR nucleic acid detection technology and independent research and development capabilities of instruments.

It has a number of independent core technologies in the fields of automation engineering, micro-precision manufacturing, immunofluorescence, nucleic acid detection and gene sequencing. Since its establishment, the company has applied for more than 60 patents and currently has 17 authorized patents. The company has two R&D centers for diagnostic reagents and instruments and equipment, totaling more than 500 square meters; it has established more than 2,000 square meters of GMP workshops and equipment production plants; it has SmartTRF new immune detection technology, nucleic acid detection technology (POCT) and three scientific services.